Top Page
Microbix Biosystms
(TSX:MBX)
Microbix Biosystms (MBX) vs. S&P 500 (SPY)
Microbix Biosystms Business Overview & Revenue Model
Microbix Biosystms Financial Statement Overview
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 23.03M | 25.39M | 16.51M | 19.08M | 18.59M | 10.52M |
| Gross Profit | |||||
| 12.92M | 15.39M | 7.48M | 11.12M | 11.04M | 4.66M |
| EBIT | |||||
| 624.37K | 3.91M | -2.74M | 2.69M | 4.84M | -524.60K |
| EBITDA | |||||
| 4.51M | 6.21M | 1.96M | 3.73M | 5.66M | -2.91M |
| Net Income Common Stockholders | |||||
| 1.92M | 3.52M | -39.48K | 1.79M | 1.63M | -6.23M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 12.87M | 12.96M | 11.61M | 13.49M | 9.99M | 92.66K |
| Total Assets | |||||
| 37.92M | 38.10M | 35.65M | 33.15M | 28.83M | 15.60M |
| Total Debt | |||||
| 6.72M | 6.40M | 6.65M | 5.82M | 7.74M | 6.17M |
| Net Debt | |||||
| -6.16M | -6.57M | -4.96M | -7.66M | -2.25M | 6.08M |
| Total Liabilities | |||||
| 10.17M | 9.80M | 11.03M | 8.21M | 10.27M | 8.98M |
| Stockholders Equity | |||||
| 27.76M | 28.30M | 24.62M | 24.94M | 18.56M | 6.62M |
| Cash Flow | Free Cash Flow | ||||
| 1.73M | 2.44M | -2.11M | 1.44M | 804.20K | -805.34K |
| Operating Cash Flow | |||||
| 3.80M | 4.35M | -1.09M | 3.47M | 2.11M | 8.57K |
| Investing Cash Flow | |||||
| -2.07M | -1.91M | -1.02M | -2.03M | -622.34K | -813.91K |
| Financing Cash Flow | |||||
| -1.46M | -1.08M | 229.21K | 2.06M | 8.41M | 802.43K |
Microbix Biosystms Technical Analysis
Microbix Biosystms Peers Comparison
Microbix Biosystms Earnings Call Summary
Microbix Biosystms Corporate Events
Microbix Biosystems Inc. announced its participation in the ESCMID Global 2025 conference, where it will showcase its innovative Quality Assessment Products (QAPs) designed to ensure the accuracy of diagnostic tests. A customer and collaborator, Labquality EQAS by Aurevia, will present results from a pilot External Quality Assessment program for Norovirus antigen detection, supported by Microbix’s QAPs. This initiative highlights Microbix’s capability to create effective controls for challenging antigen materials, enhancing its industry positioning and demonstrating its commitment to quality management in diagnostics.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Outperform.
Microbix Biosystems is positioned well with strong financial performance and positive earnings call outcomes, indicating robust growth in core business areas and strategic expansions. However, the high P/E ratio and lack of dividend yield suggest potential overvaluation. Technical indicators show mixed signals, but recent corporate actions provide additional confidence in strategic planning and financial flexibility.
To see Spark’s full report on TSE:MBX stock, click here.
Microbix Biosystems Inc. announced that its products remain exempt from new U.S. tariffs, providing a competitive edge over other international exporters facing tariffs. The company is also exploring Canadian procurement opportunities amid potential reciprocal tariffs on U.S. goods. While the outlook for its QAPs business remains strong, sales of test-ingredients, particularly antigens, have been affected by reduced demand in China. Despite these challenges, Microbix continues to expand its capabilities and remains financially robust, with significant cash reserves and ongoing strategic initiatives in diagnostics and synthetic biology.
Spark’s Take on TSE:MBX Stock
According to Spark, TipRanks’ AI Analyst, TSE:MBX is a Outperform.
Microbix Biosystems is positioned well with strong financial performance and positive earnings call outcomes, indicating robust growth in core business areas and strategic expansions. However, the high P/E ratio and lack of dividend yield suggest potential overvaluation. Technical indicators show mixed signals, but recent corporate actions provide additional confidence in strategic planning and financial flexibility.
To see Spark’s full report on TSE:MBX stock, click here.
Microbix Biosystems Inc. announced the results of its Annual and Special Meeting of Shareholders, where 42.83% of the issued and outstanding shares were represented, and all resolutions were approved, including the re-election of board members and the re-appointment of auditors. This positive outcome reflects shareholder confidence and supports the company’s ongoing operations and strategic initiatives in the life sciences sector.
Microbix Biosystems Inc. has optimized its capital structure by repaying a C$ 1.2 million mortgage and expanding its line of credit from C$ 2.0 million to C$ 4.0 million. These financial moves are expected to reduce interest expenses and provide greater strategic flexibility, allowing the company to reinvest in growth and adapt to market changes. With these changes, Microbix aims to maintain financial strength, support operations, and ensure resilience against economic uncertainties.
Microbix Biosystems Inc. has signed a Memorandum of Understanding with the Australian Centre for the Prevention of Cervical Cancer (ACPCC) to supply its PROCEEDxFLOQ brand Quality Assessment Products (QAPs) to support the accuracy of HPV testing in the Indo-Pacific region. This collaboration is part of the EPICC program, which aims to eliminate cervical cancer in the region by improving the prevention, diagnosis, and treatment of the disease. The initiative is supported by the Australian Government and philanthropic partners and seeks to extend its proven model to additional countries, enhancing access to accurate HPV testing and reducing the human toll of cervical cancer.
Microbix Biosystems Inc. recently hosted Ontario Premier Doug Ford and MPP Deepak Anand at their Mississauga facilities, highlighting their role as a leading Ontario-based life sciences company. The visit underscored the company’s contributions to healthcare through innovative diagnostic tests that improve patient outcomes and reduce costs. Microbix has benefited from over C$ 2.0 million in grant funding from Ontario’s government, which has supported the development of world-leading healthcare products and reinforced the company’s commitment to maintaining its operations in Ontario.
Microbix Biosystems Inc. has announced the issuance of 2,895,000 stock options as part of its strategy to incentivize and retain key personnel, including its board of directors, executives, and managers. These options, exercisable at $0.48 per share, are part of the company’s broader compensation program and reflect its commitment to using stock options as a tool for employee retention. The issuance is expected to have a minimal dilutive impact on shares, largely offset by ongoing share repurchases. This move underscores Microbix’s strategy to maintain a motivated workforce while managing shareholder interests.
Microbix Biosystems Inc. announced its participation in the Whistler Capital Event conference, where CEO Cameron Groome will engage with growth-oriented equity investors through a series of one-on-one meetings. This engagement aims to enhance investor awareness and establish new relationships that may lead to financing opportunities and increased market support. This initiative reflects Microbix’s strategic efforts to strengthen its position in the life sciences industry and expand its market reach.
Microbix Biosystems reported strong financial results for the first quarter of fiscal 2025, with revenues reaching $6.0 million and a net income of $0.9 million. The significant 40% year-over-year increase in revenues was mainly driven by the growth in sales of its antigen products, which saw a 118% increase. Although there was a decrease in test quality assessment product revenues due to delays in customer test-development programs, the company achieved improved gross margins of 62% through better efficiencies and pricing strategies. Operating expenses were reduced by 23% compared to the previous year, contributing to the overall profitability without reliance on non-recurring revenues from the prior year’s Kinlytic licensing deal.
Microbix Biosystems Inc. announced the scheduled release of its Q1 fiscal 2025 financial results on February 13, 2025. The company will host a webinar discussion with its executives to review these results, providing an opportunity for investors and shareholders to engage. This announcement highlights Microbix’s commitment to transparency and maintaining communication with its stakeholders, potentially impacting its market positioning and investor relations positively.
Microbix Biosystems Inc. has secured C$ 2.4 million in new equity capital through the exercise of expiring share purchase warrants. This capital will be used to enhance product development, expand manufacturing capacity, and improve operational efficiency. The financial boost demonstrates shareholders’ confidence and positions the company for greater sales and improved financial metrics, highlighting its reliability as a long-term partner in the life sciences industry.